user warning: Unknown column 'type' in 'field list' query: SELECT module, type FROM newevent_captcha_points WHERE form_id = 'user_login_block' in /var/www/flaxgr67/data/www/ on line 60.
BMS, PsiOxus to test new cancer combo
30 June 2016

Bristol-Myers Squibb and England's PsiOxus Therapeutics have announced a deal to work together on a new combination therapy targeting several different tumour types in late-stage cancer patients.

Leukaemia drug shows promise in ovarian cancer
30 June 2016

A drug approved for leukaemia has also shown promise in treating a specific type of ovarian cancer in a Cancer Research UK-funded study published in the journal Molecular Cancer Therapeutics.

60% response rate with Novartis’ rare blood cancer drug
30 June 2016

A mid-stage trial assessing Novartis' experimental rare blood cancer (midostaurin) has shown high response rates in patients with systemic mastocytosis.

Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis
30 June 2016

Cystic fibrosis (CF) clinical care guidelines exist for the care of infants up to age 2 years and for individuals ≥6 years of age.

US clears Gilead’s pan-genotypic hepatitis C therapy
29 June 2016

Gilead's Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for

Novartis picks up bispecific antibodies from Xencor
29 June 2016

Novartis has signed a collaboration and licensing deal with California biotech Xencor for access to its bispecific antibody technology and rights to develop and commercialise two of the latter's fl

Imbruvica for Chronic Graft-versus-Host Disease
29 June 2016

One week after the FDA gave Jakafi (ruxolitinib) a Breakthrough Therapy Designation for treating patients with acute graft-versus-host disease, the FDA has given another Breakthrough Therapy Design

Speedy review for Roche/Genentech’s MS drug Ocrevus
28 June 2016

US regulators are undertaking a priority review of Roche/Genentech's experimental multiple sclerosis therapy Ocrevus, which many believe has the potential to transform treatment of the disease.